Analysis of Risedronate According to USP Using the Agilent 1260 Infinity Bio-inert Quaternary LC System

Significance of the Topic

Risedronate sodium is a third-generation bisphosphonate widely used to treat osteoporosis, Paget’s disease and cancer-induced bone loss. Accurate quantification of risedronate in drug substances and finished tablets is critical for compliance with pharmacopeial standards and patient safety. Traditional stainless-steel LC systems often suffer severe peak tailing due to phosphate–iron interactions. The Agilent 1260 Infinity Bio-inert Quaternary LC System overcomes these issues by providing a completely metal-free sample path, ensuring reliable assays for phosphorylated compounds.

Objectives and Overview of the Study

This application note demonstrates the development and validation of USP methods for risedronate sodium substance and 5 mg tablets (Actonel) analysis using the Agilent 1260 Infinity Bio-inert Quaternary LC System. The study aims to verify that assays meet or exceed USP requirements for resolution, tailing factor, precision, linearity, limit of detection (LOD) and limit of quantification (LOQ).

Instrumentation Used

• Agilent 1260 Infinity Bio-inert Quaternary Pump (G5611A)
• Agilent 1260 Infinity Bio-inert High-performance Autosampler (G5667A)
• Agilent 1290 Infinity Thermostat for sample cooling (G1330B)
• Agilent 1290 Infinity Thermostatted Column Compartment (G1316C)
• Agilent 1260 Infinity DAD VL with bio-inert flow cell (G1315D)
• Agilent OpenLAB CDS ChemStation Edition for LC & LC MS, Rev. C.01.05

Methodology and Chromatographic Conditions

Sample and standard solutions were prepared according to USP monographs, using LC-grade solvents and EDTA (4.8 mM, pH 9.5) to prevent metal chelation. Separation was achieved on a 4 × 250 mm, 10 µm anion exchange column with a 4 × 50 mm guard, at 0.8 mL/min, 25 °C column temperature and 4 °C sample tray. Detection was at 263 nm.

Main Results and Discussion

System suitability and assay performance for both drug substance and tablets met or exceeded USP criteria:

• Resolution: 3.02 (substance) and 3.11 (tablets) versus minimum 2.3/2.5
• Tailing factor: ≤1.39 within 1.6 limit
• Precision (RSD): ≤0.17% for retention time and area
• Assay content: 100.9% for substance (spec 98–102%), 102.4% for tablets (spec 90–110%)
• Linearity: R² = 1.00 over 0.016–2 mg/mL
• LOD/LOQ: 0.254 µg/mL and 0.849 µg/mL
• Accuracy: 92.5–99.3% across tested levels

Practical Benefits and Applications

The metal-free flow path of the Bio-inert LC system eliminates phosphate–iron complexation, improving peak shape and robustness when analyzing bisphosphonates and other phosphorylated molecules. High throughput, sensitivity and reproducibility make this platform ideal for quality control in pharmaceutical manufacturing and research laboratories.

Future Trends and Potential Applications

Advances may include:

• Extension to other phosphorylated drug candidates and metabolites
• Integration with UHPLC and high-resolution mass spectrometry for structural elucidation
• Automation of sample preparation and online method transfer
• Use of greener mobile phases and reduced solvent consumption

Conclusion

The Agilent 1260 Infinity Bio-inert Quaternary LC System provides a robust, bio-inert solution for USP-compliant analysis of risedronate sodium in both drug substances and finished dosage forms. It delivers superior resolution, sensitivity and precision, ensuring reliable quality control of bisphosphonate pharmaceuticals.

References

1. DeRuiter J., Clark R. Bisphosphonates: Calcium Antiresorptive Agents, Endocrine Module, 2002.
2. Jeong H.M. et al. Risedronate increases osteoblastic differentiation and function through connexin 43. Biochem Biophys Res Commun, 2013.
3. Shi Y. et al. Novel direct detection method for intracellular nucleoside triphosphates using weak anion exchange LC-MS/MS. Rapid Commun Mass Spectrom, 2002.
4. Nagaoka S. et al. Adduct formation at C-8 of guanine on in vitro reaction of HCA with 2-deoxyguanosine and its phosphate esters. Jpn J Cancer Res, 1992.
5. Agilent Application Note 5991-0025EN. Analysis of phosphate compounds with the Agilent 1260 Infinity Bio-inert Quaternary LC System, 2012.
6. U.S. Pharmacopeia Monographs 35: Risedronate sodium, 4568–4571, 2012.